Results for: C_TS4CO_2023日本語出題内容 🐇 C_TS4CO_2023日本語全真模擬試験 🥗 C_TS4CO_2023日本語試験勉強書 🤟 ➡ www.goshiken.com ️⬅️で✔ C_TS4CO_2023日本語 ️✔️を検索して、無料で簡単にダウンロードできますC_TS4CO_2023日本語試験参考書

The Year in (P)review – MS 2013 – Is the Injectable Era (almost) Over?

January 31, 2013

The year 2013 will likely see the launch of two new oral agents for the treatment of multiple sclerosis – teriflunomide (already available in the U.S. as Aubagio), and BG-12. They will join fingolimod (Gilenya), the first of the oral MS drugs (following the withdrawal of cladribine). Fingolimod is indicated as a first-line (in the U.S.) or second-line (in Canada) treatment for relapsing forms of MS (RRMS). Subscribe to read more It takes 30 secon…

Pilot study of GSK-3 drug tested in AD

December 26, 2012

…A pilot phase IIa study (NCT00948259) has reported promising effects of tideglusib, a novel inhibitor of glycogen synthase-3 (GSK-3), in 30 patients with mild to moderate Alzheimer’s disease (Del Ser et al. J Alzheimers Dis 2012; epublished August 30, 2012). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

RIS: what are the risk factors for CIS/MS?

December 26, 2012

…There has been little information on the natural history of radiologically isolated syndrome (RIS) since it was first described in 2009 (Okuda et al. Neurology 2009;72:800-805). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

Targeting glutamate: the end of the monoamine hypothesis?

December 5, 2012

A number of recent papers have focused attention on the remarkable responses seen with glutamatergic agents in major depressive disorder (MDD), raising questions about the monoamine hypothesis of psychiatric disorders that has dominated biological psychiatry for a half century (Schildkraut JJ. Am J Psychiatry 1965;122:509-522). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you reg…

Neuroprotection: This is your brain on tea

December 5, 2012

The latest claimant to the neuroprotection crown is green tea, which provides therapeutic levels of the antioxidant EGCG (epigallocatechin gallate). A number of animal studies have indicated that EGCG may be beneficial in a range of disorders, including arthritis, colitis, Sjogren’s syndrome, and type 1 diabetes (Kim et al. J Nutr 2008;138:2111-2116; Oz et al. J Nutr Biochem 2005;16:297-304; Hsu et al. Autoimmunity 2007;40:138-147; Fu et al. Br J…